Elizabeth Halton

7.1k total citations
29 papers, 604 citations indexed

About

Elizabeth Halton is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Elizabeth Halton has authored 29 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 6 papers in Public Health, Environmental and Occupational Health and 6 papers in Immunology. Recurrent topics in Elizabeth Halton's work include CAR-T cell therapy research (28 papers), Acute Lymphoblastic Leukemia research (6 papers) and Biosimilars and Bioanalytical Methods (6 papers). Elizabeth Halton is often cited by papers focused on CAR-T cell therapy research (28 papers), Acute Lymphoblastic Leukemia research (6 papers) and Biosimilars and Bioanalytical Methods (6 papers). Elizabeth Halton collaborates with scholars based in United States, Switzerland and China. Elizabeth Halton's co-authors include Renier J. Brentjens, Isabelle Rivière, Michel Sadelain, Xiuyan Wang, Claudia Diamonte, Jae H. Park, Brigitte Sénéchal, Terence J. Purdon, Yvette Bernal and Yongzeng Wang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Elizabeth Halton

29 papers receiving 596 citations

Peers

Elizabeth Halton
Jeff Aycock United States
Katherine D. Cummins United States
Christina A. Bachmeier United States
Chunrong Tong China
Meg Elias United States
Birju Mehta United States
Zakaria Grada United States
Xue Lin United States
Barbara Pender United States
Mingzhi Zhang China
Jeff Aycock United States
Elizabeth Halton
Citations per year, relative to Elizabeth Halton Elizabeth Halton (= 1×) peers Jeff Aycock

Countries citing papers authored by Elizabeth Halton

Since Specialization
Citations

This map shows the geographic impact of Elizabeth Halton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth Halton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth Halton more than expected).

Fields of papers citing papers by Elizabeth Halton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth Halton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth Halton. The network helps show where Elizabeth Halton may publish in the future.

Co-authorship network of co-authors of Elizabeth Halton

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth Halton. A scholar is included among the top collaborators of Elizabeth Halton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth Halton. Elizabeth Halton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perica, Karlo, Jessica Flynn, Kevin J. Curran, et al.. (2021). Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 35(11). 3268–3271. 26 indexed citations
2.
Park, Jae H., Craig S. Sauter, M. Lia Palomba, et al.. (2021). A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. Blood. 138(Supplement 1). 96–96. 24 indexed citations
3.
Wudhikarn, Kitsada, Jessica Flynn, Isabelle Rivière, et al.. (2021). Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 138(7). 531–543. 47 indexed citations
4.
5.
Jain, Tania, Andrea Knežević, Martina Pennisi, et al.. (2020). Hematopoietic Recovery Following Chimeric Antigen Receptor T Cell (CAR T) Therapy in Hematological Malignancies. Biology of Blood and Marrow Transplantation. 26(3). S63–S64. 1 indexed citations
6.
Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Cancer Research. 79(13_Supplement). CT036–CT036. 44 indexed citations
7.
Geyer, Mark B., Isabelle Rivière, Brigitte Sénéchal, et al.. (2019). Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 4(9). 69 indexed citations
8.
Smith, Melody, Eric R. Littmann, John Slingerland, et al.. (2019). Intestinal Microbiome Analyses Identify Biomarkers for Patient Response to CAR T Cell Therapy. Biology of Blood and Marrow Transplantation. 25(3). S177–S177. 9 indexed citations
9.
Adusumilli, Prasad S., Marjorie G. Zauderer, Valerie W. Rusch, et al.. (2019). Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Clinical Trials. CT036–CT036. 8 indexed citations
10.
Perica, Karlo, Jessica Flynn, Kevin J. Curran, et al.. (2019). Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL.. Journal of Clinical Oncology. 37(15_suppl). 2520–2520. 9 indexed citations
11.
Shah, Gunjan L., Jae H. Park, Craig S. Sauter, et al.. (2019). Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. Biology of Blood and Marrow Transplantation. 25(3). S38–S39. 2 indexed citations
12.
Santomasso, Bianca, Jae Hong Park, Isabelle Rivière, et al.. (2018). Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008). Neurology. 90(15_supplement). 3 indexed citations
13.
Geyer, Mark B., Isabelle Rivière, Brigitte Sénéchal, et al.. (2018). Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy. 26(8). 1896–1905. 60 indexed citations
14.
Park, Jae H., Maria Lia Palomba, Connie Lee Batlevi, et al.. (2018). A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation. Blood. 132(Supplement 1). 224–224. 37 indexed citations
15.
Shah, Gunjan L., Jae H. Park, Craig S. Sauter, et al.. (2018). Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. Blood. 132(Supplement 1). 616–616. 1 indexed citations
16.
Halton, Elizabeth, et al.. (2017). Developing Infrastructure: Managing Patients With Cancer Undergoing CAR T-Cell Therapy. Clinical journal of oncology nursing. 21(2). 35–40. 6 indexed citations
17.
Park, Jae Hong, Isabelle Rivière, Xiuyan Wang, et al.. (2017). Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy.. Journal of Clinical Oncology. 35(15_suppl). 7008–7008. 13 indexed citations
18.
Park, Jae Hong, Bianca Santomasso, Isabelle Rivière, et al.. (2017). Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL.. Journal of Clinical Oncology. 35(15_suppl). 7024–7024. 20 indexed citations
19.
Park, Jae H., Isabelle Rivière, Xiuyan Wang, et al.. (2015). 475. Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALL. Molecular Therapy. 23. S188–S189. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeff Aycock Breakdown of academic impact, for papers by Katherine D. Cummins Breakdown of academic impact, for papers by Christina A. Bachmeier Breakdown of academic impact, for papers by Chunrong Tong Breakdown of academic impact, for papers by Meg Elias Breakdown of academic impact, for papers by Birju Mehta Breakdown of academic impact, for papers by Zakaria Grada Breakdown of academic impact, for papers by Xue Lin Breakdown of academic impact, for papers by Barbara Pender Breakdown of academic impact, for papers by Mingzhi Zhang
Rankless by CCL
2026